The following provides details for support for the amendments to Table 4 of the Specification and illustrates the amendments introduce no new matter.

In particular, the following provides sequence information as shown in originally filed Table 4 followed by the matching portion of preliminarily amended Table 4 (showing the proposed amendments).

#### Specification as Filed for SEQ ID NOS: 49 and 54:

Underlining in the original specification denotes support for amendments.

Re- gion	tipi- tope	Cone	Lib	Framework §	CDR 3	Framework 4	
Va	į	C15 C3 105 C1 S25 186 1C9 1C8	2	CVILOGEARLY ROASVIL SCREENISTS  E-VE	■SEQ ID NO: 54 as originally filed	**************************************	←SEQ ID NO: 49 as originally filed

## Specification as Amended for SEQ ID NOS: 49 and 54:

			Sequence		
Vx A	egion				
Spit	ope 1	Framework 1	CDR 1	Framework 2	CDR 2
		Framework 3	CDR3	Pramework 4	Seq 10 No
C9	1	QVKLQQ3GABLVRPGASVKLSCKTSGY38T	SYMM	MAXKOG&@GCEMIC	Mihronseirprokren
	1	MATLITUDKESSTÄYMQLGSPTSEDSAVYYCAR	GIYYVYDGGRWYAMDY	WGQGTTVTVSS	69
			<u> </u>		
		G			
109	2	QVqLkg9GAELVRPGVGVKi9CR <del>u</del> 9GYtFi	DYAVE	WYEQshaksLEWIG	vistyygdadyNpkPkg
	t	kATLTVnFSSnTAYMeLorlTSEDSALYYCAR	Rokg AMDY	WGGGTeVTVSS	54

#### Specification as Filed for SEQ ID NO: 63:

Re- tion	Epi-	Clone	Lib		eW1	
Bron.				Framework !	C.E.	OR 1
	2	1A)	2	evelves ordivendorskils cated for	DXXXX	
		451.	2		89-G	
		€.39	8	Q-Q-Q8-KEA	****	
		C23	8	C-C-CKkA	*****	
		2G3	2	**************************************	8-2-	
		3C3	2	A X X X	S-A	
		3F4	2	. E.S	S-A	◆SEQ ID NO: 0
		3144	2		S-X	as originally fi

### Specification as Amended for SEQ ID NO: 63:

384	2	Ε	#igKLVESGGOLVkPGGS1KLSCABSGFTPS	SMSYa	WvRQtPehRLEWVA	TISDOGTETYYTDaVKG
	1		RFTISAIMAKHULYLOMSHLMSBOTAMYYCHA	alpyáhy Dy	WGqGTaVTVSS	63

## Specification as Filed for SEQ ID NOS: 68 and 69:

Re-	Epi-	Clone	1.05		
gion	tope	CIONE	1.11/	Framework i	CDR I
	3	183	2	EVOLOESCIZZVOPCESLÄLSCAASCIFTFS	SYLVAN
		1C6	2	QI.viQ.vvvvvvv	TRAIT
		2136	2	VKLVESGF-L-KPSQSLSLTCTVTGYSIT-	D- X683
		1635	2	QQAELA-VXNKXY	SEQ ID NO: 68
		1166	2	Q - AEL K A - VER E T T	SEO ID NO: 69

as originally filed

#### Specification as Amended for SEQ ID NOS: 68 and 69:

1G5	2	gVQLQqSGaelVOPGasvkaSCKASGyTFt ka7lvvUtSsataYmQlaSCtaEDxAVYYCAR	e Ywt: S	Elgi	aMDy.	WVkQr9GqGLEWig WCQQTmVIVSS	diypgagatnynekfKa 68	
186	2	K EVQLQqSGaelV <del>Q</del> HQaSVkmSCkASGyTft RafilyDbSqsfxYmDlaStbsfbsiyyyGar	diwet.	E't owl	aNEDv	WVkQrPGqCLEWig	dlypDagatmynekíks	1

### Specification as Filed for SEQ ID NOS: 72-80:

Clone	Lib*	Framework 1	CDR I	Framework 3	Framework 4	
285	1	DIELTOS PATMEAS POSEVINTO	SASS	OVPIRES GSGSGTS VSLTIS SHEARDSATVYC	POSOTKLELER	SEO ID NO: 7
39	1		****	I.A	*********	
95	2		8	L-V	G1	SEQ ID NO. 7
3	1		****	1	A	SEQ ID NO: 7
25	į		-¥\$	1 V	AI	SEQ ID NO: 7
86	2	**************************************	RA-KSV	-L-AR-DFT189VD-V	A	SEQ ID NO: /
C9	2	STAY-L-ORA-IS-	RA-ESV		gI	SEQ ID NO: 7
DK .	2	********		J.A		SEQ ID NO: 7
G7	2		****		A	SEQ ID NO: 7 SEO ID NO: 8

## Specification as Amended for SEQ ID NOS: 72-80:

Clone	ope 1	T.W	3 0000 1	Two and a	3 7057 7
CIONS	1 212	Framework 1 Framework 3	CDR 1 CDR 3	Framework 2 Framework 4	CDR 2 Seq ID
C15	1.	DIELTOSPALMSASPGEKVIMTC  G-GVPIPFEGSGSGTEVSLTISMMEREDSATYYC	SASS SVSMMY 'QQWSSYPFT	WYQQKPGSSPRLLIY FGSGTXLELKR	DYSNLAS 72
C9	1	DIGLTOSPAIMSESPGEKVILTC  G-GVPABPSGSGSGTSYSLTIBSVEAZDAATYYC	SASS SVSyMh QQySgYPlT	WfQQKPGtSPkpwIY FG@GTKLEiKR	sTSNLAS 73
105	2	DIELTOSPAIMAASPGEKVIITC  ⊈⊕VPVRFSGSGSGTSVSLTISAMEAEDGATTYC	SASSe iSaSnlh QQWqSYPlT	WYQQKsetapkpwlY PGgGTELEiks	gtsmlas 74
C1	1	DIELTÇSPAIMSASPGEKUIMTC  Gevpvkfsgsgsgtsyslitiskmeaedaatyyc	SASS SVSYMY QQMSSYPIT	WYQQEPGSSPELLIY PGaGTELELER	DYSNEAS 75
\$25	1	DIELTOSPALMASPGERVILTC  STOPPORFEGGGGGTEVELTISEMEAEDBATTYC	SvSSs iSeSn1h QQWSSYFIT	WYQQKsGtSPkpwIY PGaGTKLEiKB	gTSHLAS 76
186	2	DIELTOSPASIausiggrafisC  Gaipassposgsytdfildtingvæaddvatttc	ratesudaygnaf#h S COsnedPpT	MAGGRACAMPETER  MAGGRACAMPETER	raSNLeS
1.09	2	DIELTQSPAslavSlQqralisC G #1PsRFSGSGSrTdEtLTInpvEAdSvATYYC	ra¥esvdsygmSiMh S OOsnedPyT	WYQQNPSqpFkiLIY FGG <del>PSW</del> STKLEIKA	rashbes 78
LES	2	DIELTOSPAIMSASEGERVINTC  G **OPartsGsGsGtsysltismmpasdaatyyc	SASS SVS/Mb QQMSSnPlT	WYQQKsGLSPkrwIY FGaGTKLELKE	DYSKLAS 79
167	2	DIBLTUSPAINSASPGEKVINTC  G GVPARFSGSGSGISYSLTISANEAEDAATYYC	SASS SVSYMh QOWSSnPlt	WYQQKsGtSPkrwlY FQaGTYLELKR	DYSKLAS 80

## Specification as Filed for SEQ ID NOS: 81-88:

Clone	Libr	Framework I	CDR i	CDR 3	Framework 4
A)	2	DISELTOS FASEAVSLOGRATISC	SASESVOSVOSICINES C	SPANIED TOTAL	PSTRILSTER SEQ ID NO
11	2	**************************************	***********		SEQ ID NO
39	1		*************		SEO ID NO
25	Ł	**************		E P-	\$ SEO ID NO
G5	2		£ \$ \$V - 7 >	RSS7	EQAGN- & SEQ ID NO
C3	2	EMSA-P-EXYFTT-	HQ -	RESY	DOMON SEO ID NO
1.4	2	-T1985A-P-EEVINT-	SS SV-Y-Y	Wasy.D.	SEQ ID NO
114	2	ATTACA PERVINI	8- VSS-YL	WSST-P.	SEO ID NO

# Specification as Amended for SEQ ID NOS: 81-88:

			<u>H</u>	<u>G</u> <u>I</u>	
ìA1	2	DIELTQSPASLAVSLGQRATISC	RASESVDSYGNSFMS	MAÖÖKBEÖBBKTTIA	LASNLES
	1	GVPARPSGSGSRIDFILTIDPVEADDAATYYC	QQWGGYPPT NI	NEDPYT FORGIKLESKR	81
1F1	12	DIEUTQSPtSLAVSLGQRAVTISC	RASESVDSYGNSFMH	WYQGKPGQPPKLLIY	Laskles
	3	GVPARPSGSGSKIDFTLTIDPVEADDAATYYC	QQ <del>-CAYFI</del> T NNEDPY	FG#GTXLE#KR	82
C39	1	DIELTQSPASLAVSLGTRATISC	RASESVOSYGNSFWH	WYQQKPGQPPKLLIY	LASNLES
		GVPARFSGSGSRTDFTLTIDFVEADDAATYYC	20 <del>/46/2/11</del> 1	POSCIKLERKR	83
			NNEDPY	<u>G</u> <u>I</u>	***************************************
C25	1	DIELTOSPASLAVSLOGRATISC	RASESVDSYGhSFMq	MAGGKEGGEEKTTIR	rASNLEp
		GiparpsGsGSgtDFtLfthPVEADDvATVYC	QC <del>XXXYF1</del> T	FGSGTKLEHKR	84
			SNEDPF	<u>I</u>	***************************************
2G5	2	DIELTOSPAimsaSpGekvtttC	sass svsymg	WfQQKPGtsPkLwIY	stSNLas
		CVPARPSUSUS@TwysLTIsrmHAeDARTYYC	QQ <del>amedYa</del> r2	9'G9'ddqagnKS	85
			RSSYPY		
303	12	DIELTOSPAimeaSpGekvtrtC	RASESVESYGHSFRC	WfOGMPGtsPkLwIY	scSNLaS
		GVPARPSGSGSGTsysL/TIsymEAeDAATYYC	QQ <del>sacdPy</del> T	PGSGdqagtiKR	86
	,	***************************************	RSSYPY		
		M			
384	T 2	DtELTOSPAimsaSpGekvt#tC	sASs sysymy	WYCOKPGssPrLLIY	dr.SNLa5
		GVPVRFSGSGSgTsysLTIsrmEAeDAATYYC	QQWSS <del>welm</del> Y	PPT FGSGTKLEWIRI	87
384	2	DIELTOSFRimssSpGekvt#tC M	RASSS vssSylG	WYCOKPGmsPrLLIY	disNLaS
		OVPVRPSGSGSGTavaL/TISTMEAGDARTYYC	OOMSS <del>ari</del> 2	PGSGTKLE-KR	98

YPP

## Specification as Filed for SEQ ID NOS: 94 and 95:

Clone	Sequence <sup>b</sup>	
	CDR 2	Framework 3
183 268	SASKLAS	CVPREFSCRCSCFS YELFTESVEARDAATYVC SEQ ID NO: 94 SEQ ID NO: 95 as originally filed

## Specification as Amended for SEQ ID NOS: 94 and 95:

		<u>SL</u>			
173	2	DIELTQSPASMSASPGEKVTWTC	KATSS VSSSYLH	NYQQESGASPELWIY	SASMLAS
	i	GVPSRFSGSGSGTSY <del>LS</del> TISSVEAEDARTYYC	OGAIGABAA	PGGGTKLEIKR	94
258	5	DIELTOSPtiMaASPGEKITITC	sAsSS igSnYLH	WYQQKpGfSPKL11Y	#tSNLAS
1		CVPaRFSGSGSGTSYSLTIga EREDVATYYC	QQqssiPYT	FGGGTKLEIKE	R 95

The following illustrates that the amendments to the claims to correct the sequence identifiers do not introduce new matter.

The relevant parts of Table 11 on page 85-88, paragraph [0241] of the Specification <u>as originally filed</u> are reproduced below.

[0241] Table 11 amino acid sequences for affinity matured and/or modified antibodies.

Heavy Cl	nai <b>n</b> s			
Clone	Framework 1	CDR1	Framework 2	CDR2
huC25	QVQLQESGGGLVQPGGSLRLSC AASGFTPS (SEQ ID	DYYMY(SEQ ID NO:87)	WVRQAPGKGLEW VA(SEO ID	TISDGGSYTYYPD SVKG(SEO ID
122.00.077   177(200 22   1277(200 120 120 120 120 120 120 120 120 120				

.

Heavy Ch	ains cont'd			
	Framework 3	CDR3	Framework 4	
huC25	RFTISRDNSKNTLYLOMNSLRA EDTAMYYCSR(SEQ ID	YRYDDAMDY(S EO ID	WGQGTLVTVSS( SEO ID	
1	NO:126)	NO:127)	NO:128)	
	I SERVICE WERE ASSESSED AND WERE AND		1 AND AND A SHIP AND A STATE OF STATE O	1

. .

Light Ch	ains			
Clone	Framework 1	CDR1	Framework 2	CDR2
huC25	EIVLTQSPATLSLSPGERATIS	RASESVDSYGH	WYQQKPGQAPRL	RASNLEP(SEQ
	C(SEQ ID NO:156)	SFMQ(SEQ ID	LIY(SEQ 1D	ID NO:159)

. . .

Light Cha	uns cont'd.			
Clone	Framework 3	CDR3	Framework 4	
huC25	GIPARFSGSGSGTDFTLTISSL EPEDFAVYYC(SEQ ID NO:196)	QQSNEDPFT(S EQ ID NO:197)	FGQGTKVEIKR( SEQ ID NO:198)	

The relevant parts of Table 11 as amended pursuant to the <u>Preliminary Amendment</u> filed April 19, 2004 are reproduced below.

At pages 85-88, amend Table 11 as follows:

[0241] Table 11 amino acid sequences for affinity matured and/or modified antibodies.

Heavy C	nains			
Clone	Framework 1	CDRI	Framework 2	CDR2
huC25	QVQLQESGGGLVQPGGSLRLSC AASGFTFS (SEQ ID NO:86138)	DYYMY (SEQ ID NO: 87139)	WVRQAPGKGLEW VA(SEQ ID NO:88140)	TISDGGSYTYYPD SVKG(SEQ ID NO: <del>89</del> 141)

..

Heavy Ch	ains cont'd			
	Framework 3	CDR3	Framework 4	
huC25	RFTISRDNSKNTLYLQMNSLRA EDTAMYYCSR(SEQ ID NO: <del>126</del> 178)	YRYDDAMDY(S EQ ID NO:127179)	WGQGTLVTVSS (SEQ ID NO: <del>128</del> 180)	

• • •

Light Cha	ins			
Clone	Framework 1	CDRI	Framework 2	CDR2
huC25	ETVLTQSPATLSLSPGERATIS C(SEQ ID NO: 156208)	RASESVDSYGH SFMQ(SEQ ID NO: <del>157</del> 209)	WYQQKPGQAPRL LIY(SEQ ID NO: <del>158</del> 210)	RASNLEP(SEQ ID NO: <del>159211</del> )

. .

Light Cha	ins cont'd.			
Clone	Framework 3	CDR3	Framework 4	
huC25	GIPARFSGSGSGTDFTLTISSL EPEDFAVYYC(SEQ ID NO: <del>196</del> 248)	QQSNEDPFT (SEQ ID NO: <del>197</del> 249)	FGQGTKVEIKR (SEQ ID NO:198250)	

The sequence information of SEQ ID NOS: 139, 141, 179, 209, 211, and 249, as shown in the enclosed Sequence Listing, as well as their one letter code sequences are as follows.

As shown in the Sequence Listing:  <210> 139  <211> 5  <212> PRT  <213> Artificial Sequence	One-Letter Code:	Sequence in the Specification as Amended in the Preliminary Amendment:
<220> <223> single chain antibody fragment <400> 139 Asp Tyr Tyr Met Tyr 1 5	SEQ ID NO: 139 DYYMY	DYYMY(SEQ ID NO:87139)
<210>  41 <211>  7 <212> PRT <212> PRT <213> Artificial Sequence <220> <223> single chain antibody fragment <400>  141 Thr Ile Ser Asp Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly	SEQ ID NO: 141 TISDGGSYTYYPDSVKG	TISDGGSYTYYPD SVKG(SEQ ID NO:89141)
<210> 179 <211> 9 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment <400> 179 Tyr Arg Tyr Asp Asp Ala Met Asp Tyr 1 5	SEQ ID NO: 179 YRYDDAMDY	YRYDDAMDY(S EQ ID NO:±27179)

<210> 209 <211> 15 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment		RASESVDSYGH
<400> 209 Arg Ala Ser Glu Ser Val Asp Ser Tyr Gly His Ser Phe Met Gln 1 5 10 15	SEQ ID NO: 209 RASESVDSYGHSFMQ	SFMQ(SEQ ID NO: <del>157</del> 209)
<210>211		
<2113 7 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment		
<400> 211 Arg Ala Ser Asn Leu Glu Pro 1 5	SEQ ID NO: 211 RASNLEP	RASNLEP(SEQ ID NO: <del>159</del> 211)
<210> 249 <211> 9 <212> PRT <213> Artificial Sequence		
<220> <223> single chain antibody fragment		
<400> 249 Gln Gln Ser Asn Glu Asp Pro Phe Thr 1 5	SEQ ID NO: 249 QQSNEDPFT	QQSNEDPFT (SEQ ID NO: <del>197</del> 249)